SSA
HZNP

Schonfeld Strategic Advisors’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Schonfeld Strategic Advisors’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-20,000
Closed -$20K – 2519
2023
Q2 		$20K Buy
+20,000
New +$2.11M ﹤0.01% 1893
2023
Q1 		– Sell
-15,500
Closed -$473K – 3005
2022
Q4 		$473K Buy
+15,500
New +$1.29M ﹤0.01% 1558

Other funds holding HZNP

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
VWA
Valued Wealth Advisors Holladay, Utah $275M AUM 24.94% 1-Year Est. Return
FSWA
Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $683M AUM 22.58% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Schonfeld Strategic Advisors's HZNP Position: Q4 2023 in Review

Schonfeld Strategic Advisors sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 538,836 shares — an estimated $62.3M sold.

Schonfeld Strategic Advisors first reported a position in HZNP in Q1 2016 and held it in 22 quarters. The position peaked at $62.3M in Q3 2023. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

  • Schonfeld Strategic Advisors reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 538,836 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $62.3M.
  • Schonfeld Strategic Advisors first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2016 and held it in 22 quarters.
  • Schonfeld Strategic Advisors's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $62.3M in Q3 2023.
  • 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Schonfeld Strategic Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.